From 2016 to 2022, the global hospital acquired disease testing market is expected to continue expanding, a Credence Research report found, according to Run Direct Magazine.
Here are five takeaways:
1. By 2022, the market is expected to hit $1.63 billion.
2. The market was valued at $523 million last year.
3. In 2015, the hospital-acquired pneumonia and urinary tract infection segment collaboratively had a 50 percent market share.
4. North America has the largest regional presence in the market due to a high number of hospital stays and prevalence of healthcare-acquired infections.
5. Diatherix, Roche, Cantel Medical, Qiagen, Cephid and bioMeriux are key market vendors.
More articles on quality & infection control:
10% boost in hand hygiene compliance reduced HAIs by 6%: 4 takeaways
3 tips when disclosing medical errors
Valeritas names Erick Lucera new CFO — 5 points
